GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-Allergy Drugs Advisory Committee votes in favor of what could become the first-approved LAMA/LABA combo for COPD but wants postmarket safety study in patients with more severe cardiovascular disease.